

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
GOODS PROCUREMENT CONTRACT**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that on 27 May 2022, Shenzhen Zhong Ji Health Science Company Limited* (深圳市中基健康科學有限公司), an indirect wholly-owned subsidiary of the Company (“**Zhong Ji Health**”), and Shenzhen Naber Medicine Company Limited* (深圳市南北醫藥有限公司) (“**Naber Medicine**”) entered into the goods procurement contract (the “**Procurement Contract**”). Pursuant to this, Naber Medicine will purchase 100,000 bottles of ZJ1 acerola sheet in batches from Zhong Ji Health for a total amount of RMB31,800,000 (equivalent to approximately HK\$37,524,000). The products shall be delivered in batches according to the demand of Naber Medicine, with the volume of each batch specified in the bill of lading.

INFORMATION ON NABER MEDICINE

Naber Medicine was founded in 1987 and has been engaged in the pharmaceutical and healthcare industry for over 30 years. Its principal business covers: pharmaceutical wholesale and distribution, pharmaceutical delivery, pharmacy chains, medical device agency and health product R&D and manufacturing, internet pharmaceutical e-commerce platforms and it holds three major brands of chain store, namely “Naber Pharmacy” (南北藥行), “Baohua Pharmacy” (寶華藥行) and “Jianhua Pharmacy” (健華

* For identification purposes only

藥業)。In 2021, there were more than 1,600 outlets of Naber Medicine, primarily located at large and mid-sized cities in China, such as Shenzhen, Guangzhou, Dongguan, Huizhou, Jiangmen, Western Guangdong and Wuhan.

REASONS FOR AND BENEFITS OF ENTERING INTO THE PROCUREMENT CONTRACT

The board of directors believes that the entering into of the Procurement Contract enables the Group to utilize Naber Medicine's comprehensive, resourceful and multidimensional marketing channel model to develop an extensive and in-depth pharmaceutical retail channel for the Group, further improving the presence of the Group in the field of longevity science.

For the purpose of this announcement only, the conversion of RMB to HK\$ is based on the exchange rate of RMB1.00 to HK\$1.18.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 30 May 2022

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Yan Yifan (*Chief Executive Officer*)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Lee See Barry
Mr. Wang Ning
Prof. Huang Cibo

Non-executive Directors

Dr. He Yiwu
Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.